Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 06/22 | 06/24 | 40,000 sh2 trades | $30.20avg. | $1,208,159 | −62.2% | |
Kooij Louise FrederikaChief Accounting Officer | NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 05/26 | 05/27 | 65,000 sh | $35.69 | $2,319,850 | −72.7% |
NewAmsterdam PharmaNAMS | Open-market sale | 03/11 | 03/12 | 44,619 sh2 trades | $30.42avg. | $1,357,229.51 | −81.2% | |
Louis G. LangeDirector | NewAmsterdam PharmaNAMS | Open-market sale | 03/06 | 03/10 | 28,186 sh | $29.41 | $828,950.26 | −100.0% |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 03/05–03/09 | 03/09 | 300,000 sh3 trades | $30.30avg. | $9,090,868.39 | −81.2% | |
NewAmsterdam PharmaNAMS | Open-market sale | 03/02 | 03/02 | 443,707 sh | $33.25 | $14,753,257.75 | −71.8% | |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 02/24–02/26 | 02/26 | 306,293 sh7 trades | $34.53avg. | $10,575,091.2 | −63.8% | |
NewAmsterdam PharmaNAMS | Open-market sale | 02/20 | 02/24 | 45,481 sh2 trades | $35.31avg. | $1,605,997.94 | −45.9% | |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/27–01/28 | 01/29 | 72,428 sh2 trades | $32.25avg. | $2,335,859.52 | −74.8% | |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/23–01/26 | 01/27 | 72,572 sh4 trades | $33.29avg. | $2,415,843.11 | −74.9% | |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/20–01/21 | 01/22 | 100,000 sh5 trades | $32.61avg. | $3,260,617.98 | −63.1% | |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/07 | 01/09 | 11,582 sh | In footnote | No stated value | −3.0% | |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/05 | 01/07 | 5,118 sh | $33.25 | $170,173.5 | −13.5% | |
Johannes Jacob Pieter KasteleinChief Scientific Officer | NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/05 | 01/07 | 6,000 sh | $33.25 | $199,500 | −7.5% |
Kooij Louise FrederikaChief Accounting Officer | NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 01/05 | 01/07 | 2,647 sh | $33.25 | $88,012.75 | −17.6% |
NewAmsterdam PharmaNAMS | Open-market sale10b5-1 plan | 25/12/23–25/12/26 | 25/12/29 | 145,000 sh3 trades | $35.84avg. | $5,196,740.65 | −90.6% | |
James N. TopperDirector | NewAmsterdam PharmaNAMS | Open-market buy | 25/09/15 | 25/09/17 | 660 sh | $23.70 | $15,642 | +0.0% |
NewAmsterdam PharmaNAMS | Open-market sale | 25/09/09 | 25/09/10 | 150,000 sh2 trades | $25.83avg. | $3,874,016.8 | −90.9% | |
James N. TopperDirector | NewAmsterdam PharmaNAMS | Open-market buy | 25/09/08 | 25/09/10 | 1,260 sh | $24.99 | $31,487.4 | +0.0% |
Kooij Louise FrederikaChief Accounting Officer | NewAmsterdam PharmaNAMS | Open-market sale | 25/09/03 | 25/09/05 | 18,073 sh | $25.09 | $453,451.57 | −54.6% |